当院におけるSGLT2阻害薬80症例での検討 : SGLT2阻害薬は最強の糖尿病性腎症治療薬である

We analyzed ８０ patients with type ２ diabetes who were administered SGLT２ inhibitor at our clinic. Side effects such as muscle weakness, vaginal candidiasis and urinary ketone-positive were observed, but there were no hypoglycemia cases that needed the drug reduction. There were only ２ cases of discontinuation of treatment and the reason for high patient satisfaction seemed to be due to weight loss being likely to occur. Combined use of SGLT２ inhibitor in obese patients being treated with SU drug and insulin preparation resulted in a decrease in body weight and HbA１c value and dose reduction of SU drug and insulin preparation were possible. After administration, body weight, systolic blood pressure, diastolic blood pressure, HbA１c, uric acid and GPT levels decreased significantly. As I already reported, when SGLT２ inhibitor was administered to ２９ patients with diabetic nephropathy, albuminuria decreased about ５０％ after ６ months, about ７０％ after１year and about ８０％ after １．５ years and these reduction rates were much higher than those of RAS inhibitors which efficacy against diabetic nephropathy has already been established, and SGLT２ inhibitors have been reported to be the strongest drug for treating diabetic nephropathy and the decrease in eGFR value has been reported to be due to a decrease in glomerular internal pressure. Analysis in ８０ cases of this time also showed a decrease in eGFR value during the administration period, and it seems that the reduction of eGFR value works to maintain the renal function in the long term.